One Equity buys in to China Medicine

    | BY

    clpstaff &clp articles

    One Equity Partners (OEP), the global private equity investment arm of JP Morgan Chase & Co, has bought a controlling stake in China Medicine Corporation…

    One Equity Partners (OEP), the global private equity investment arm of JP Morgan Chase & Co, has bought a controlling stake in China Medicine Corporation for US$69.6 million. The purchase was made through OEP's wholly-owned affiliate, OEP CHME Holdings.

    China Medicine is a developer and distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines and nutritional and dietary supplements. The funds will be used to finance acquisitions and capital expenditures and for working capital.

    This premium content is reserved for
    China Law & Practice Subscribers.

    • A database of over 3,000 essential documents including key PRC legislation translated into English
    • A choice of newsletters to alert you to changes affecting your business including sector specific updates
    • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
    For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]